Press release - 08/01/2009 ILM – Screening methods Optical screening methods are of huge importance for a broad range of analytical issues. Fluorescence-based methods are highly significant for their high sensitivity amongst other things. Important technological developments have focused for example on reducing sample volumes increasing sample throughput high-throughput screening HTC or on information content high-content screening HCS. With regard to screening methods the ILM is currently…https://www.gesundheitsindustrie-bw.de/en/article/press-release/ilm-screening-methods
Article - 07/12/2008 New kilo laboratory for R&D Boehringer Ingelheim has recently officially opened a new kilo laboratory in Biberach. The laboratory produces pharmaceutically active substances for use in pharmaceutical development toxicity testing and the early clinical development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-kilo-laboratory-for-r-d
Press release - 07/10/2008 GENEDATA SCREENER® – specialised data analysis for the identification of high-potential lead structures Genedata AG has developed a modular software system known as Genedata Screener that is tailored to screening and hit-to-lead applications. Dr. Timo Wittenberg who works at the companys site in Constance Germany told us about the advantages of the software for identifying high-potential leads.https://www.gesundheitsindustrie-bw.de/en/article/press-release/genedata-screener-specialised-data-analysis-for-the-identification-of-high-potential-lead-structures
Dossier - 29/09/2008 Drug screening - higher throughput, quicker and more effective thanks to automation Over the last few years automation has revolutionised the search for pharmaceutical compounds. Using methods such as high-throughput screening or high-content screening it is possible to analyse thousands of molecule activities very quickly. https://www.gesundheitsindustrie-bw.de/en/article/dossier/drug-screening-higher-throughput-quicker-and-more-effective-thanks-to-automation
Article - 02/09/2008 Screening with high quality and high throughput The Early Discovery department of the research-based pharmaceutical company Nycomed GmbH deals with early drug research from the identification of targets to the generation of lead structures. This process involves high-throughput drug screening. On behalf of www.bio-pro.de Michael Statnik talked with Dr. Stefanie Polej about the process of the automated analysis of molecule activities in the Constance-based company.https://www.gesundheitsindustrie-bw.de/en/article/news/screening-with-high-quality-and-high-throughput
Article - 22/06/2008 Nycomed sells oncology programs to 4SC Eight projects in the preclinical and first clinical stage will be transferred to 4SC. Nycomed decided not to further invest in oncology RD activities. 4SC develops drug candidates for inflammatory diseases cancer and infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-sells-oncology-programs-to-4sc